CMTx Biotech
Christopher Czura is the VP, Scientific Affairs at CMTx Biotech. Christopher holds a Ph.D. Molecular Microbiology from Stony Brook University.
This person is not in any offices
CMTx Biotech
CMTx Biotech is a clinical-stage biopharmaceutical company that is developing an orally administered small molecule for the treatment of sepsis patients at risk of Acute Respiratory Distress Syndrome (ARDS) and/or Multiple Organ Dysfunction Syndrome (MODS), including those infected with SARS-CoV-2 (COVID-19).